Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 4Recruiting 2Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Other solid neoplasm 1

Conditions

Ovarian Neoplasms 507Uterine Cervical Neoplasms 361Endometrial Neoplasms 304Breast Neoplasms 128Colorectal Neoplasms 112Neoplasms 98Fallopian Tube Neoplasms 90Carcinoma, Non-Small-Cell Lung 87Stomach Neoplasms 83Pancreatic Neoplasms 79Lung Neoplasms 72Melanoma 68Prostatic Neoplasms 66Carcinoma, Ovarian Epithelial 65Neoplasm Metastasis 63Triple Negative Breast Neoplasms 51Vulvar Neoplasms 49Squamous Cell Carcinoma of Head and Neck 49Head and Neck Neoplasms 45Esophageal Neoplasms 43Uterine Neoplasms 40Peritoneal Neoplasms 40Urinary Bladder Neoplasms 38Carcinoma, Hepatocellular 35Carcinoma, Renal Cell 34Uterine Cervical Dysplasia 31Papillomavirus Infections 31Colonic Neoplasms 31Sarcoma 30Recurrence 29

Interventions

Paclitaxel 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Platinum-resistant Recurrent Ovarian Cancer × Gynecologic × Clear all
NCT06434610 2026-05-05

A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.

Shanghai Jiaolian Drug Research and Development Co., Ltd

Phase 2 Recruiting
90 enrolled
Gynecologic

Platinum-resistant Recurrent Ovarian Cancer

NCT06687070 2025-02-26

APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST

Ascentage Pharma Group Inc.

Phase 1 Recruiting
50 enrolled
GynecologicOther solid neoplasm

Platinum-resistant Recurrent Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡